


Faster, cheaper blood tests

Christopher Ball, CEO

Out of hospital, accurate blood results take a day



Patients

- Extra journeys
- Needles
- Delayed care


Doctors

- Missing information
- Need to follow up patients

Payers

- Capital costs
- Inefficient care

Our solution offers faster, cheaper blood tests



Prick of blood

Single-use test cards

- Up to 8 tests per card

Handheld reader

- Similar accuracy to lab
- 10 minute test time


Company and progress

UK limited company

Lab at King's Cross, London


- 2 mature technologies
- 6 employees
- 7 patent families
- 12 months from product launch

“Works-like/looks-like” prototype



20 different tests confirmed lab-quality performance
- 3 in our prototype test card

Milestones to breakeven



Management team

Chris Ball
CEO



- Ex-CEO, OPK Biotech
- Launched £200m blood glucose meter for J&J in Europe
- Ex-VC and doctor

Gareth Jones
CTO



- Ex-Head of Biology, UK Government's Daresbury Lab
- Serial inventor for diagnostic companies

Dick Sandberg
Chairman



- Chair, Oxford Immunotec and OBS Medical
- Founder of Dianon Systems

The key is our two proprietary chemistries

Nanocrystals
diagnostic label

Channel
coatings



- Miniaturised lab performance
- 10 x lower reader cost and cost per test
- Robust practical real-world testing
 - Real-world point-of-care performance



We own over 40 granted patents in the major global diagnostic markets

Jupiter could save health systems millions

Country	Blood tests per year	Cost per year	Potential saving per year for routine out-of-hospital tests
Germany ¹	1 billion	£4 billion	£300-500 million
USA	7 billion ²	£48 billion ³	£2-4 billion
UK ⁴	750 million	£3 billion	£250-400 million

Source


1. http://www.vdgh.de/media/file/3541.VDGH_Leporello_Auf_einen_Blick_2013_engl_WEB.pdf
2. <http://www.acla.com/value-of-lab-testing/>
3. The Economist: Young Blood: 27 June 2015: US lab services market \$60 billion
4. GPOnline.com: CCGs can save £750m on tests: 18 Jan 2013

Launch markets


IVF clinics in Germany and Spain position us for rapid expansion

- Fast adoption
- Confirmed demand
- Specialist distributors seeking a better product

EU worth £100-200m¹
Germany and Spain: £10-15m



Revenue model




Competition

	Practical	Low price	Lab quality	Panels of tests
Jupiter	✓	✓	✓	✓
Hospital labs (NHS, TDL)	✗	✓	✓	✓
Desktop analysers (Roche, Biomérieux)	✗	✗	✓	✓
Mini-analysers (Alere, Abbott)	✓	✗	✗	✗
Rapid tests	✓	✓	✗	✗

Funds: topping up our EIS series A round

- Raised £1.6m on pre-money of £2m
 - Syndicate of EIS funds and UK/HK angels
- Room for £500k+

Use of proceeds



Shareholders	% equity
Angels	41%
Early stage funds	40%
Mgmt & founders	15%
SuperNova	13%
Others	1%

Financial forecast

GBP ('000s) Y/E 31 Dec	2016	2017	2018	2019	2020
Sales		188	1,367	4,745	10,022
Gross profit		134	1,077	3,990	8,679
Net profit	(845)	(1,268)	(1,435)	352	3,708
Readers placed		44	590	2,670	5,954
Test panels sold ('000s)		15	144	532	1,099

Raise further £5 million in
Q4-2017 on 1st sales

Exit: acquisition by a large diagnostic company

Potential exit point	Target date	Comparable acquisitions
1. Proof of market <i>First sales</i>	Q3 2017	Vivacta (3 yrs from Series A) £56 million on launch Novartis (2009)
2. Growth accelerating <i>Cashflow breakeven</i>	2019-2020	Handylab (9 yrs from Series A) £170 million on <£1m revenues Becton-Dickinson (2009)
3. Competitive against labs <i>Rapid growth</i>	2021 onwards	Cholestech (18 yrs from Series A) £245 million on £48m revenues Alere (2007)

Why invest in us?

- Clear route to market and validated demand
- Differentiated and protected point-of-care platform
- Clear product roadmap
- Highly competent management team
- Attractive exit opportunities

